VIATRIS INC. O.N.

Viatris reported Q2 revenue up about 4.9% year over year and management raised fiscal 2026 guidance across key metrics. Billionaire-led funds held stakes in the stock as it traded near $16, up ~33% year-to-date. The FDA approved the once-weekly Gwyn Lo contraceptive patch, a fast-acting meloxicam formulation is under review and two late-stage trials (selatogrel and cenerimod) will report in early fiscal 2027. Valuation looks attractive (forward non-GAAP P/E ~6.6, EV/EBITDA ~7) but tariff risk and looming changes to generic exemptions in 2028 pose material downside for its import-reliant portfolio. » Mere på finance.yahoo.com

Viatris reported adjusted EPS of $0.69 for Q2 2026 (expectation $0.61) and revenue of $3.76 billion versus expected $3.67 billion, and subsequently raised its full-year guidance. Free cash flow and margins improved; adjusted EBITDA was $1.2 billion and gross margin rose to 57.5%. Debt fell to about 2.9x. The stock dipped slightly premarket as investors weighed potential H2 risks such as a new procurement policy in China, production interruptions in Nashik and intensified competition. » Mere på de.investing.com

The FDA has approved Gwyn Lo, a once-weekly contraceptive patch from Viatris containing norelgestromin and ethinylestradiol. The patch is intended for women of childbearing potential with a BMI under 30 kg/m² and delivers 220 mcg norelgestromin and 20 mcg ethinylestradiol per day. Approval was based on the Phase III Luminous study, which showed a Pearl Index of 4.14 and complete detachment of only 1.3% of applied systems. Common side effects included application-site reactions, irregular and heavy withdrawal bleeding, and nausea; Gwyn Lo is contraindicated in smokers over 35 and in women with BMI ≥30 kg/m². Viatris expects to launch the product later this year. » Mere på de.investing.com

Viatris shares rose to a 52‑week high of $17.68, driven by strong price performance (+90.82% year‑to‑date) and a market capitalization of $20.6 billion. The company beat Q1‑2026 expectations with adjusted EPS of $0.59 (consensus $0.51) and revenue of $3.52 billion. Viatris also reported positive Phase‑3 results for the IgAN drug VR‑205 in Japan, and the FDA has accepted the approval filing for a rapid‑acting meloxicam formulation (PDUFA date 27.12.2026). InvestingPro rates the stock as undervalued; management has executed aggressive buybacks and expects to be profitable this year. » Mere på de.investing.com

Viatris shares rose to a new 52-week high of $17.53; market capitalization stands at $20.26 billion. Year-to-date the stock has climbed 41% and is up 94% over the past year. Viatris beat Q1 2026 analyst expectations with adjusted EPS of $0.59 and revenue of $3.52 billion. The company also reported positive Phase‑3 results for VR‑205 in Japan and the FDA has accepted the approval pathway for MR‑107A‑02 (PDUFA date 27.12.2026). According to InvestingPro, the calculated fair value indicates further upside potential. » Mere på de.investing.com